These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37250185)

  • 1. Trends and determinants of prevalence, awareness, treatment and control of dyslipidaemia in canton of Geneva, 2005-2019: Potent statins are underused.
    Marques-Vidal P; Chekanova V; de Mestral C; Guessous I; Stringhini S
    Int J Cardiol Cardiovasc Risk Prev; 2023 Sep; 18():200187. PubMed ID: 37250185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence, treatment and control of dyslipidaemia in Switzerland: still a long way to go.
    Firmann M; Marques-Vidal P; Paccaud F; Mooser V; Rodondi N; Waeber G; Vollenweider P
    Eur J Cardiovasc Prev Rehabil; 2010 Dec; 17(6):682-7. PubMed ID: 20700055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five year trends in dyslipidaemia prevalence and management in Switzerland: the CoLaus study.
    Antiochos P; Marques-Vidal P; Waeber G; Vollenweider P
    Nutr Metab Cardiovasc Dis; 2015 Nov; 25(11):1007-15. PubMed ID: 26321470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of clinical and genetic risk factors with management of dyslipidaemia: analysis of repeated cross-sectional studies in the general population of Lausanne, Switzerland.
    Chekanova V; Abolhassani N; Vaucher J; Marques-Vidal P
    BMJ Open; 2023 Feb; 13(2):e065409. PubMed ID: 36810165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1999-2009 Trends in prevalence, unawareness, treatment and control of hypertension in Geneva, Switzerland.
    Guessous I; Bochud M; Theler JM; Gaspoz JM; Pechère-Bertschi A
    PLoS One; 2012; 7(6):e39877. PubMed ID: 22761919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence, awareness, treatment, and control of dyslipidemia and associated factors among adults in Jordan: Results of a national cross-sectional survey in 2019.
    Pengpid S; Peltzer K
    Prev Med Rep; 2022 Aug; 28():101874. PubMed ID: 35801002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National high prevalence, and low awareness, treatment and control of dyslipidaemia among people aged 15-69 years in Mongolia in 2019.
    Pengpid S; Peltzer K
    Sci Rep; 2022 Jun; 12(1):10478. PubMed ID: 35729323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of dyslipidaemia in statin-treated patients in Ireland: Irish results of the DYSlipidaemia International Study (DYSIS).
    Horgan S; Crowley J; Feely J; McAdam B; Shanahan E; Vaughan C
    Ir J Med Sci; 2011 Jun; 180(2):343-9. PubMed ID: 21400212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS).
    Raal FJ; Blom DJ; Naidoo S; Bramlage P; Brudi P
    Cardiovasc J Afr; 2013 Sep; 24(8):330-8. PubMed ID: 24240385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. General practitioners' adherence to guidelines on management of dyslipidaemia: ADDITION-Denmark.
    Graversen L; Christensen B; Borch-Johnsen K; Lauritzen T; Sandbaek A
    Scand J Prim Health Care; 2010 Mar; 28(1):47-54. PubMed ID: 19929180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and factors associated with statin use in high-risk patients with type 1 diabetes from a specialized diabetes unit.
    Amor AJ; Ortega E; Giménez M; Cofán M; Blanco J; Pané A; Boswell L; Vinagre I; Esmatjes E; Conget I
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Oct; 66(8):512-519. PubMed ID: 31000451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Dyslipidaemia Using an Algorithm of Lipid Profile Measures among Newly Diagnosed Type II Diabetes Mellitus Patients: A Cross-Sectional Study at Dormaa Presbyterian Hospital, Ghana.
    Anto EO; Obirikorang C; Annani-Akollor ME; Adua E; Donkor S; Acheampong E; Asamoah EA
    Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31330902
    [No Abstract]   [Full Text] [Related]  

  • 13. Single and mixed dyslipidaemia in Canadian primary care settings: findings from the Canadian primary care sentinel surveillance network database.
    Asghari S; Aref-Eshghi E; Godwin M; Duke P; Williamson T; Mahdavian M
    BMJ Open; 2015 Dec; 5(12):e007954. PubMed ID: 26656980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends and determinants of time in bed in Geneva, Switzerland.
    Gubelmann C; Guessous I; Theler JM; Haba-Rubio J; Gaspoz JM; Marques-Vidal P
    J Clin Sleep Med; 2014 Oct; 10(10):1129-35. PubMed ID: 25317094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyslipidaemia in the elderly: to treat or not to treat?
    Katsiki N; Kolovou G; Perez-Martinez P; Mikhailidis DP
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):259-278. PubMed ID: 29303009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in cardiovascular risk factor prevalence among Lithuanian middle-aged adults between 2009 and 2018.
    Laucevičius A; Rinkūnienė E; Petrulionienė Ž; Ryliškytė L; Jucevičienė A; Puronaitė R; Badarienė J; Navickas R; Mikolaitytė J; Gargalskaitė U; Dženkevičiūtė V; Kutkienė S; Gimžauskaitė S; Mainelis A; Šlapikas R; Gurevičius R; Jatužis D; Kasiulevičius V
    Atherosclerosis; 2020 Apr; 299():9-14. PubMed ID: 32179208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence, awareness and treatment of type 2 diabetes mellitus in Switzerland: the CoLaus study.
    Kaiser A; Vollenweider P; Waeber G; Marques-Vidal P
    Diabet Med; 2012 Feb; 29(2):190-7. PubMed ID: 21883431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilisation of lipid-lowering therapies in outpatient settings in Poland: epidemiological survey Economedica Dyslipidaemia 2015.
    Szymański FM; Płatek AE; Ryś A; Semczuk-Kaczmarek K; Krzowski B; Wróbel K; Filipiak KJ
    Kardiol Pol; 2018; 76(3):648-654. PubMed ID: 29313565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and types of persistent dyslipidemia in patients treated with statins.
    Reiner Ž; Tedeschi-Reiner E
    Croat Med J; 2013 Aug; 54(4):339-45. PubMed ID: 23986274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
    Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
    Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.